ANGPTL3 and residual atherosclerotic risk: from lipid metabolism to therapeutic targeting

Area of Science:

• Cardiovascular Medicine
• Lipid Metabolism
• Pharmacology

Background:

• Many patients achieve low-density lipoprotein cholesterol (LDL-C) targets but still face high cardiovascular event risk.
• Elevated triglyceride-rich lipoproteins and remnants contribute significantly to this residual risk.
• Angiopoietin-like protein 3 (ANGPTL3) is a key regulator of lipoprotein metabolism and a potential therapeutic target.

Purpose of the Study:

• To review the biological, genetic, and clinical evidence supporting ANGPTL3 as a therapeutic target.
• To provide an overview of novel ANGPTL3-targeted therapies.
• To explore new perspectives for cardiovascular prevention and lipid management.

Main Methods:

• Integration of data from human genetic studies.
• Analysis of pharmacologic interventions targeting ANGPTL3.
• Review of ANGPTL3's role in lipoprotein lipase and endothelial lipase inhibition.

Main Results:

• ANGPTL3 inhibition consistently improves lipid profiles.
• Therapies targeting ANGPTL3 lower apolipoprotein B-containing lipoproteins.
• These effects are independent of LDL receptor function.

Conclusions:

• ANGPTL3 inhibition is a promising strategy for managing residual cardiovascular risk.
• Novel ANGPTL3-targeted therapies offer new avenues for cardiovascular prevention.
• Understanding ANGPTL3's role is crucial for advancing lipid management.